Cannabis mergers and acquisitions didn’t disappear in 2026, they just stopped looking like the splashy, all-stock combinations that defined the industry’s earlier boom years. Deal activity is real, but it’s smaller, quieter, and structured very differently than what multi-state operators were doing a few years ago.
Rescheduling Changed the Math, Not the Mood
The proposed move of marijuana from Schedule I to Schedule III, tracked by the Drug Enforcement Administration, has been treated as a turning point for the industry’s finances. Removing the Section 280E tax burden would materially improve cash flow for profitable operators, and that alone changes how buyers and sellers model a deal.
But rescheduling normalizing the tax math is not the same thing as rescheduling triggering a wave of deals on its own. Buyers still need a target that’s actually worth owning, and that’s where most 2026 activity has stalled.
“A bad business will remain a bad business.”
Why Public MSOs Are Sitting on Their Hands
Multi-state operators (MSOs), the publicly traded companies that dominated cannabis M&A headlines a few years ago, are largely capital-constrained heading into 2026. Between debt loads, limited access to traditional bank financing, and stock prices well below their earlier highs, most public operators don’t have the cash or the currency to go on an acquisition spree the way they once did.
That’s a big part of why the big, public, all-stock mega-mergers that used to make headlines have mostly gone quiet. The buyers who would have led that kind of deal simply aren’t positioned to right now.
Where the Real Activity Is Happening
Consolidation hasn’t stopped, it’s moved. According to reporting from Forbes, most of the deal-making happening now is private, and it’s built on a different set of tools than the stock-swap mega-deals of the past:
- Stock-for-stock deals between smaller, closely held operators looking to combine footprints without a cash outlay.
- Earnouts that tie part of the purchase price to the acquired business actually hitting performance targets, shifting risk back onto the seller.
- Seller and private credit financing, filling the gap left by banks that still won’t lend against federally illegal cannabis assets.
These structures let smaller operators, including licensed dispensary operators in tightly regulated markets like New York, combine or exit without needing a public acquirer or a large cash check.
“The early wave of the cannabis tsunami will be driven by structures, not by sentiment.”
Singles, Not Grand Slams
The consistent read from people watching the space is that 2026 is a year of small, structured deals rather than transformative combinations. A few reasons that pattern is likely to hold for a while:
- Valuations are still resetting. Buyers and sellers haven’t fully converged on what cannabis assets are worth in a post-rescheduling-but-still-federally-illegal world.
- Regulatory uncertainty remains. Rescheduling has been proposed, not finalized into a fully settled framework, and buyers are pricing that uncertainty into every deal.
- Capital is scarce and selective. Whoever has clean access to capital, whether that’s private equity, family offices, or well-capitalized private operators, has significant leverage over sellers who need liquidity.
What This Means for Operators
- Sellers should expect structure, not just a check. Earnouts and seller financing mean the purchase price is rarely all paid on day one.
- Buyers with real capital access have the advantage. Cash, or access to private credit, is currently worth more in negotiations than it has been in years.
- Clean operations matter more than ever. With buyers being selective, well-run, compliant businesses are the ones actually getting offers.
Frequently Asked Questions
Did cannabis M&A activity stop in 2026?
No, it shifted. Large public, all-stock mega-mergers have slowed, but private deal-making using stock swaps, earnouts, and seller financing has continued, according to industry reporting.
Did Schedule III rescheduling cause a wave of cannabis acquisitions?
Not directly. Rescheduling improves the tax and cash flow picture for profitable operators, which supports deal-making, but it hasn’t by itself triggered a surge in transactions. A rescheduled substance still needs a business worth buying behind it.
Why aren’t public multi-state operators doing more acquisitions?
Most public MSOs are capital-constrained, carrying debt and facing limited access to traditional financing, which leaves them with less cash and less appetite for large acquisitions than in previous years.
Daniel Levinson is a cannabis industry business development and M&A consultant with roughly a decade of experience working with cannabis brands, startups, and operators, including in regulated medical cannabis markets such as Israel. He writes for Just Weed Strains on cannabis business, legal, and dispensary topics, drawing on his industry and deal-side experience. Connect with him on LinkedIn.